Tips and tricks: how Parkinson’s patients can discover their own coping strategies
PD in Practice
Author: Mariella GrazianoPublished: 11 August 2016
Prep: Cook: Serves:
Mariella Graziano, president of the Association of Physiotherapists in Parkinson’s Disease Europe, has experience of managing people with Parkinson’s across all disease stages, and one of the most useful ways to coping with the condition often lies with the patients themselves, she argues
People with Parkinson’s are capable of developing their own creative ways to overcome daily difficulties. Over the years, health professionals have observed with admiration the effectiveness of these unique, self-created strategies that sometimes work where medication occasionally fails.
Health professionals are increasingly aware of the creative and effective power of people with Parkinson’s to help maintain their independence. In 2014 the European Physiotherapy Guideline for Parkinson’s Disease (Keus et al, 2014) made a recommendation to take into account the trick that patients developed to overcome specific problems, evaluate their safety and adequacy and to improve the strategy if required (1).
In a video presented by Anke H Snijders, MD and Bastiaan R Bloem, MD, (2010) a 58-year-old man with severe freezing of gait surprised health professionals when he was able to jump on his bicycle and cycle safely along the road with astounding agility – fending off his freezing in the process. When he jumped off the bicycle, his freezing of gait would resume.
Another ingenious strategy created by a 50-year-old man with Parkinson’s was bouncing a tennis ball during ‘off’ periods. During ‘off’ periods his arms shake violently.
Then, one day a friend threw an orange at him, and to his surprise he caught it and the tremors stopped. So, he experimented and started throwing a ball in the air and catching it again and again with his shaking hand. The tremor stopped during this action, but returned whenever he stopped. After a lot of practicing, he noticed that by bouncing the ball he could get up from the chair and it helped even to walk and run better.
Don’t underestimate the value of self-management
These cases are a source of inspiration for therapists to creatively apply and teach their patients appropriate tricks according to their specific needs. Patients’ discovery of movement strategies and cues for themselves supports the present approach of physiotherapy. It is also proof that we should actively encourage our patients to contribute to their own disease management.
European Physiotherapy Guideline for Parkinson’s Disease Samyra Keus et al (2014)
‘Cycling for Freezing of Gait’, Anke H Snijders, MD and Bastiaan R Bloem, MD (2010) in The New England Journal of Medicine
Physiotherapy and Parkinson’s disease
Between 2004 and 2007 Mariella Graziano, on behalf of the European Parkinson’s Disease Association (EPDA), organised a series of physiotherapy workshops held across the world. The aim was to share the strategies invented by people with Parkinson’s – like the ones mentioned in this article – with professionals to encourage their own contribution to disease management.
To learn more tricks and tips to help with Parkinson’s symptoms visit the EPDA ‘Coping strategies’ page here.
Learn coping tricks and strategies for carers at Parkinson’s summit
The Caregiver's Summit aims to equip carers with the tools to take charge
2 days ago
Wearable device for Parkinson’s disease raises $10m in funding
UK-based tech company Charco Neurotech has secured $10 million in seed investment funding to support the launch of a non-invasive wearable device designed for people with Parkinson’s disease. CUE1 is a circular device worn on the sternum, which is designed to help alleviate Parkinson’s symptoms through specialised vibrations that are personalised for each patient. The investment round, which was co-led by venture capital company Amadeus Capital Partners and growth fund managers Parkwalk Advisors, is the largest European seed financing in 2021 for a heath technology device – and the sixth largest globally. Lucy Jung, co-founder and CEO of Charco Neurotech, said: “This funding will enable us to proceed with our first, limited launch, while we work to ensure our manufacturing line is robust and produces consistent high quality devices.” Charco also recently announced a new partnership with the European Parkinson’s Disease Association (EPDA), to help increase the availability of Charco’s…
An international team led by the University of Ottawa in Canada will study whether the scent-processing nerves inside the nose may play a part in the development of Parkinson’s disease. The researchers will explore potential connections between inflammation, environmental exposures in the nasal cavity, odour processing centres in the brain and Parkinson’s-related genes. The scientists hope that if the study indicates that Parkinson’s starts in the nose, early signs of the condition could potentially be detected sooner. This research, which will use human and animal models, has been made possible by a US $9m grant from the Aligning Science Across Parkinson’s (ASAP) initiative, which aims to improve understanding of the causes of the condition. “This grant will allow us to explore an understudied but important aspect of Parkinson’s, which could lead to new approaches for early treatment and prevention,” said Professor Michael Schlossmacher, team leader of the study.
Study finds gene therapy may restore effects of Parkinson’s drug
Levodopa is a drug commonly used to treat Parkinson’s as it helps to increase dopamine levels in the brain and improve problems with movement. In later stages of the condition, however, this treatment can become less effective. Now, findings from a US preclinical study have suggested that a new gene therapy may help to restore the effects of levodopa in people with the condition. The researchers used mice models of Parkinson’s to test the effects of the gene therapy, targeting a small region in the brain where dopamine-releasing neurons are present. They found that the therapy increased the neurons’ ability to convert levodopa to dopamine – and discovered that damage to the mitochondria in dopamine-releasing neurons may be enough to trigger Parkinson’s onset. The scientists hope their findings will encourage the development of therapies to preserve the function of these neurons, and support patients in the later stages of Parkinson’s.